Join Medicilon at Precision In Drug Discovery & Preclinical Summit (San Francisco)

We are very pleased to announce that Medicilon will participate in the 16th Precision In Drug Discovery & Preclinical Summit (PDDP) West Coast. It kicks off on Nov 14th, 2022 in San Francisco, California. 

Our Executive VP and Head of IDSU (International Discovery Service Unit), Dr. Xuedong Dai will be speaking at the PDDP Summit. Topic title is "Medicilon: One-Stop Shop For Drug R&D Services - From Ideas To IND" on November 14 at  09:55-10:25 AM  PST. 

Dr. Dai also will participate in the panel discussion titled "Overcoming The Barriers to Curing Diseases with AI and ML" on November 15 at 12:00-01:00 PM. The other invited participants areManoj Jadhav (CEO, ISHA Therapeutics), Jonathan Gast (Application Scientist of Nanome), and  Hariprasad Vankayalapati (CSO, Biolexis Therapeutics). The panel discussion is moderated by Andrea Small Howard (President and CSO of GB Sciences). 

Medicilon American team will be present throughout the event. We welcome you to join us at the forum! Please stop by our booth and chat how our services and capabilities would support your research needs and expedite your drug discovery and development programs.

Booth Number: 10

The Precision in Drug Discovery & Preclinical event will be a unique platform for the largest bio-pharmaceutical hub in the region to network and discuss collaboration in order to achieve their discovery and scientific strategies. This gathering will showcase the progress and latest research trends that include new compounds, drug design, synthesis methods and technologies that advance the science from leaders in the pharma-biotech and academic spaces. With an innovation-focused agenda, pre-scheduled meetings between potential collaborators and a host of reliable service providers, the summit is designed to help attendees find solutions to their most pressing research challenges in 2021 and beyond. To learn more, please visit their website. 

November 14

November 15

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D services for pharmaceutical enterprises and scientific research institutions around the world.

Based on key links of drug R&D, we focus on the demand for innovation and the development of the global pharmaceutical industry. With our experience in serving domestic and foreign biomedical industries, we have built an integrated technical platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, in a bid to provide comprehensive preclinical new drug R&D for the global biomedical industry.

18+

More Than 18 Years of Experience in New Drug R&D

268

Projects Successfully Approved with NMPA, FDA, EMA, and TGA

1710+

Active Clients Worldwide

3500+

New Drug Discovery Scientists and Service Personnel

740,000+

Square Feet of Laboratory Floor Space

The mission of Medicilon International Discovery Service Unit is to provide high quality, efficient and cost-effective synthetic chemistry, drug design, and new drug candidate compound services to global pharmaceutical companies.  We are stride to meet the research and development needs of the clients in various chemical fields of pre-clinical new drug research, shorten the cycle of drug R&D, and reduce the cost of drug R&D.

Medicilon  International Discovery Service Unit has a management team and lab personnel with a rich background of studying abroad, a world-leading synthesis and analysis laboratory with installed state-of-the-art instruments and equipment.  In order to provide clients with better services, the International Discovery Service Unit keeps up with new developments and new technologies in drug design and synthesis, such as artificial intelligence/machine learning (AI/ML), proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC), direct functionalization of inert carbon-hydrogen bonds, photoredox reactions, and flow chemistry, etc.

Medicilon Drug discovery services include chemistry (synthetic chemistry, medicinal chemistry) and biology. In terms of chemistry, it can undertake multi-dimensional business such as custom synthesis, compound library construction, SAR compound synthesis and screening, compound structure and biological activity optimization.

The medicinal chemistry team deeply cross-integrates chemistry and biology into each project, and flexibly uses the powerful expertise of computational chemistry to aid the compound design process. At the same time, Medicilon extensively uses advanced drug discovery technology, including PROTAC targeted protein degradation technology, DEL DNA-encoded small molecule compound library screening technology, ADC antibody drug conjugation technology, etc. Medicilon efficiently promotes customers' drug research and development projects, controls costs, and improves quality!